Increased hs-CRP and Sepsis Influence the Occurrence of Thrombocytopenia in Severe and Critically Ill COVID-19 Patients Receiving Anticoagulants
Abstract
BACKGROUND: Despites its benefits, as one of COVID-19 principal treatments, anticoagulant raises a significant concern regarding the anticoagulant-related thrombocytopenia. However, up to date, there is lack of study examining anticoagulantinduced thrombocytopenia during COVID-19, hence this study was conducted to determine the factors inducing anticoagulant-induced thrombocytopenia in COVID-19 patients.
METHODS: An observational cross-sectional study of 106 anticoagulant-treated COVID-19 subjects was conducted. Blood serum was drawn from subjects, then platelets, prothrombin time (PT), activated partial thromboplastin (aPPT), international ratio (INR), D-dimer, ferritin, fibrinogen, and high-sensitivity C-reactive protein (hs-CRP), were measured. For thrombocytopenia risk assessment, the 4T score was calculated. To assess the risk of thrombocytopenia. Statistical analysis using Chi-square and Mann-Whitney U test were performed and followed by multivariate analysis to examine the correlation among the thrombocytopenia risk factors.
RESULTS: Significant differences were identified in the length of stay (LOS) (p=0.04), disease severity (p=0.021), sepsis (p=0.006), hs-CRP (p=0.003), and mortality rate (p=0.028) between thrombocytopenia and nonthrombocytopenia groups. A multivariate analysis through linear and logistic regression disclosed an increase in hs-CRP (OR=-0.29; p=0.045) and sepsis (OR=4.32; p=0.03) that precipitate the thrombocytopenia events.
CONCLUSION: In severe and critically ill COVID-19 patients, the occurrence of thrombocytopenia was followed by an increase in inflammatory parameters such as D-dimer, fibrinogen, ferritin, hs-CRP and prolonged coagulation. The increase in hs-CRP and sepsis may raise the risk of thrombocytopenia, especially in severe and crtically ill cases of COVID-19.
KEYWORDS: COVID-19, anticoagulant, thrombocytopenia, inflammation, infectious disease
Full Text:
PDFReferences
Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020; 395(10235): 1517–20, CrossRef.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’’ in COVID-19.’ J Infect. 2020; 80(6): 607–13, CrossRef.
Warkentin TE, Kaatz S. COVID-19 versus HIT hypercoagulability. Thromb Res. 2020; 196: 38–51, CrossRef.
Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020; 99(6): 1205–8, CrossRef.
Meiliana A, Patellongi I, Wijaya A. The role of high concentration of resistin in endothelial dysfunction through induction of proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and chemokin monocyte chemotactic protein-1 (MCP-1). Indones Biomed J. 2009; 1(2): 24–30, CrossRef.
Kartika R, Wibowo H. Impaired function of regulatory T cells in type 2 diabetes mellitus. Mol Cell Biomed Sci. 2020; 4(1): 1–9, CrossRef.
Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021; 76(4): 412–20, CrossRef.
Price LC, McCabe C, Garfield B, Wort SJ. Thrombosis and COVID-19 pneumonia: the clot thickens! Eur Respir J. 2020; 56(1): 2001608, CrossRef.
Sriram KPA. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Am J Physiol - Adv Physiol Educ Physiol J. 2021; 101(2): 545–67, CrossRef.
Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(9): 2103–9, CrossRef.
Haimei MA. Pathogenesis and treatment strategies of COVID-19-related hypercoagulant and thrombotic complications. Clin Appl Thromb/Hemost. 2020; 26: 1076029620944497, CrossRef.
Kartika RW, Alwi I, Suyatna FD, Yunir E, Waspadji S, Immanuel S, et al. Advance-platelet rich fibrin and hyaluronic acid combination improves interleukin-6 and granulation index in diabetic foot ulcer patients. Indones Biomed J. 2021; 13(2): 170–7, CrossRef.
Flaczyk A, Rosovsky RP, Reed CT, Bankhead-Kendall BK, Bittner EA, Chang MG. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. Crit Care. 2020; 24(1): 559, CrossRef.
Franco-martinez C, Gonzalez J, Foster D, Gutierrez C, Gonzalez J. Guidelines for Anticoagulation in Hospitalized COVID-19 Patients ≥ 18 Years of Age. San Antonio: University Health System; 2020, article.
Hardy M, Lecompte T, Douxfils J, Lessire S, Dogné JM, Chatelain B, et al. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thromb J. 2020; 18: 17, CrossRef.
Zhu Y, Zhang J, Li Y, Liu F, Zhou Q, Peng Z. Association between thrombocytopenia and 180-day prognosis of COVID-19 patients in intensive care units: A two-center observational study. PLoS One. 2021; 16(3): e0248671, CrossRef.
Bashash D, Hosseini-Baharanchi FS, Rezaie-Tavirani M, Safa M, Akbari Dilmaghani N, Faranoush M, et al. The prognostic value of thrombocytopenia in COVID-19 patients: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020; 8(1): e75, PMID.
Putranto TA, Yusuf I, Murtala B, Wijaya A. Intra arterial heparin flushing increases cerebral blood flow in chronic ischemic stroke patients. Indones Biomed J. 2016; 8(2): 119–26, CrossRef.
Lingamaneni P, Gonakoti S, Moturi K, Vohra I, Zia M. Heparin-induced thrombocytopenia in COVID-19. J Investig Med High Impact Case Rep. 2020; 8: 2324709620944091, CrossRef.
Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. Vasc Med. 2020; 25(2): 160–73, CrossRef.
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Pedoman Tatalaksana COVID-19. 2nd Ed. Pedoman Tatalaksana COVID-19. Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI; 2020, article.
Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017; 129(21): 2864–72, CrossRef.
Matsumura Y, Nakada TA, Oda S. Relationship between the 4Ts scoring system and the antiplatelet factor 4/heparin antibodies test in critically ill patients. Acute Med Surg. 2013; 1(1): 37–44, CrossRef.
Uaprasert N, Tangcheewinsirikul N, Rojnuckarin P, Patell R, Zwicker JI, Chiasakul T. Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. Blood Adv. 2021; 5(21): 4521–34, CrossRef.
Behrens E. Heparin Induced Thrombocytopenia in Patients with. 2021; 5(21): 4521–34, CrossRef.
Favaloro EJ, Henry BM. The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with. 2021; 43(4): 547–58, CrossRef.
Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020; 2(11): 2048–58, CrossRef.
Keski H. Hematological and inflammatory parameters to predict the prognosis in COVID-19. Indian J Hematol Blood Transfus. 2021; 37(4): 534–42, CrossRef.
DOI: https://doi.org/10.18585/inabj.v15i1.2045
Copyright (c) 2023 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
